Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report

Xin Chen; Yazhou Zhang; Nu Zhang; Yongsheng Ge; Weidong Jia

doi:10.2147/OTT.S217123

Lenvatinib combined nivolumab injection followed by extended right hepatectomy is a feasible treatment for patients with massive hepatocellular carcinoma: a case report

Onco Targets Ther. 2019 Sep 9:12:7355-7359. doi: 10.2147/OTT.S217123. eCollection 2019.

Authors

Xin Chen^{1

2}, Yazhou Zhang^{1

2}, Nu Zhang^{1

2}, Yongsheng Ge^{1

2}, Weidong Jia^{1

2}

Affiliations

¹ Department of General Surgery, The First Affiliated Hospital of USTC, Division of Life Science and Medicine, University of Science and Technology of China, Hefei, Anhui Province 230001, People's Republic of China.
² Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, Hefei, Anhui Province 230001, People's Republic of China.

Abstract

Hepatocellular carcinoma (HCC) is a highly aggressive malignant tumor. The survival of advanced HCC is very poor. In this case study, we describe the treatment of a 69-year-old woman diagnosed with massive hepatocellular carcinoma, the use of lenvatinib in combination with nivolumab injection in the preoperative adjuvant treatment of advanced massive hepatocellular carcinoma, and the final taking extended right hepatectomy. Molecular targeted drugs and immunotherapy controlled patient's condition to create time and conditions for surgery. After surgery, AFP was greatly reduced, no recurrence of the residual liver and no metastasis in the distance. This treatment is the gospel of patients with advanced liver cancer.

Keywords: HCC; combination therapy; hepatectomy; lenvatinib; nivolumab injection.